Article

Akorn gains stake in Aciex

Akorn has acquired a minority stake in Aciex Therapeutics, a Westborough, MA-based pharmaceutical company focused on developing first-in-class products to treat ocular diseases. Akorn is a niche pharmaceutical company engaged in the development, manufacture, and marketing of multisource and branded pharmaceuticals. The terms of the deal and the size of the stake were not disclosed.

Lake Forest, IL-Akorn has acquired a minority stake in Aciex Therapeutics, a Westborough, MA-based pharmaceutical company focused on developing first-in-class products to treat ocular diseases. Akorn is a niche pharmaceutical company engaged in the development, manufacture, and marketing of multisource and branded pharmaceuticals. The terms of the deal and the size of the stake were not disclosed.

Aciex’s product pipeline includes both clinical stage and pre-investigational new drug assets. The acquisition was accompanied by a global licensing deal that gives Akorn rights to a novel over-the-counter eye-care product, and a manufacturing agreement for one of Aciex’s lead prescription candidates.

“We are excited to partner with Aciex and have the opportunity to bring novel over-the-counter and prescription eye-care products to the market,” said Raj Rai, Akorn’s chief executive officer. “With this partnership, we have rounded out our strategy in ophthalmology to include generics, branded, and over-the-counter pharmaceuticals.” 

Akorn’s ophthalmology business markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes. Akorn also offers custom research and development and manufacturing services for injectable and ophthalmic products.

In May, Akorn acquired Advanced Vision Research, a firm that specializes in the over-the-counter dry eye market.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.